治愈HCV对全身炎症和骨密度,质量和营业额的影响
Christina K Psomas1, Elsa Lellouche-Slama2, Susan Langan3
1European Hospital Marseille, Marseille, France.
用直接作用抗病毒药物 (DAA) 治疗型肝炎病毒 (HCV) 减少了炎症,但没有显著改变骨密度. 然而,HIV-HCV同时感染的个体在治疗后表现出骨形成标志物的增加.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 慢性肝炎C病毒 (HCV) 感染与骨质疏松症和骨折有关,可能是由于全身炎症,特别是在HIV-HCV联合感染中.
- 直接作用抗病毒药物 (DAA) 有效治疗HCV并减少炎症,但它们对骨健康的影响仍未得到充分研究.
研究的目的:
- 评估通过DAA治疗治愈HCV对骨参数和全身炎症的影响.
- 为了比较HCV单一感染,HIV-HCV共感染个体和健康的参考组的骨结果和炎症标志物.
主要方法:
- 双能X射线吸收仪 (DXA) 扫描和椎骨分数 (TBS) 用于评估骨矿物质密度 (BMD) 和质量.
- 骨循环标志物 (BTM) 和炎症生物标志物 (sTNFR-1/2,sCD163,IL-6) 在基线和随访时被测量.
- 在DAA治疗后,HCV感染组和基准组之间比较了骨和炎症标志物的变化.
主要成果:
- 治愈HCV导致系统性炎症标志物 (sTNFR1,sTNFR2,sCD163) 的显著减少.
- 与基准组相比,在整体HCV组中没有观察到 BMD,TBS 或 BTM 的显著变化.
- 同时感染HIV-HCV的个体显示骨形成标志物P1NP的显著增加,以及治疗后腰椎和部全骨 BMD 增加的趋势.
结论:
- 用DAA消除HCV有效减少全身炎症,但短期内不会显著改变骨参数.
- 艾滋病毒-HCV共感染个体骨形成标记的增加表明潜在的骨恢复,值得进一步长期调查.
更多相关视频
07:51Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
